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Abstract: Osteoporosis is the most common bone disease. Low levels of oestrogens or testosterone are risk factors for primary 
osteoporosis. The most common cause of secondary osteoporosis is glucocorticoid treatment, but there are many other secondary 
causes of osteoporosis. Osteoporosis can be secondary to anti-oestrogen treatment for hormone-sensitive breast cancer and to 
androgen-deprivation therapy for prostate cancer. Zoledronic acid is the most potent bisphosphonate at inhibiting bone resorption. In 
osteoporosis, zoledronic acid increases bone mineral density for at least a year after a single intravenous administration. The efficacy 
and safety of extended release (once-yearly) zoledronic acid in the treatment of osteoporosis is reviewed.
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Introduction
Osteoporosis is the most common bone disease. 
Osteoporosis (porous bone, thinning of bone) 
affects .10 million people in the US, including 
2 million men, at an annual cost of US$17 billion.1 
Osteoporosis is associated with low bone mass 
(low bone mineral density) giving rise to vertebral 
fractures and non-vertebral fractures. The vertebral 
fractures lead to stooped posture, loss of height, and 
back pain. An important site of non-vertebral is hip 
fractures, and nearly 2 million hip fractures occur 
each year in the US as a result of osteoporosis.1 After 
hospital discharge, one in five people die within one 
year of hip fracture, and one in three require residen-
tial care placement.1 The main defect in osteoporosis 
is incomplete refilling of resorption lacunae, which 
leads to gradual thinning or perforation of trabeculae, 
impaired trabecular connectivity and deterioration of 
bone microarchitecture.2
Low levels of oestrogens or testosterone are impor-
tant risk factors for osteoporosis. Thus, postmenopausal 
women with low levels of oestrogens are at increased 
risk of osteoporosis. Older men have lower levels 
of testosterone, and reduced activity of the enzyme 
aromatase, which is responsible for transforming 
testosterone to oestrogens in men, and this leads to 
reduced levels of oestrogens.3 Osteoporosis can also 
be secondary e.g. to glucocorticoid treatment for 
transplantation. Osteoporosis can be secondary to 
anti-oestrogen treatment for hormone-sensitive breast 
cancer and to androgen-deprivation therapy for pros-
tate cancer. Bisphosphonates (e.g. zoledronic acid) 
are used in the treatment of primary and secondary 
osteoporosis.
Many of the bisphosphonates are administered orally 
at regular intervals (daily, weekly, monthly) with the 
subject having to fast beforehand and stand or sit in an 
upright position for 30 minutes afterwards to minimise 
alimentary tract side effects. This procedure is unpopu-
lar with subjects and many stop taking them. Thus, the 
adherence to oral bisphosphonates is low.4 Zoledronic 
acid (1-hydroxy-2-imidazol-1-yl- phosphonoethyl bis-
phosphoric acid) is a bisphosphonate used intravenous 
predominantly on an annual basis in the treatment of 
primary osteoporosis.
There is evidence that serious adverse effects with 
zoledronic acid (e.g. osteonecrosis of the jaw) are 
mainly observed when zoledronic acid is used more 
than once-annually, which is usually in the prevention 
of bone loss associated with the treatment of cancer.5 
This review is predominantly of the efficacy and safety 
of once-yearly zoledronic acid in the treatment of pri-
mary osteoporosis or secondary osteoporosis due to 
glucocorticoid use, where osteonecrosis of the jaw is 
not an issue, but also considers the use of once-yearly 
zoledronic acid in the osteoporosis due to the treat-
ment of cancer. When evidence for once-yearly zole-
dronic acid is not available, evidence with six-monthly 
zoledronic acid is considered. Trials with fracture 
endpoints are given priority over those with surro-
gate endpoints e.g. bone mineral density. Firstly, the 
effect of zoledronic acid in primary osteoporosis is 
considered, and then the effect of zoledronic acid in 
secondary osteoporosis such as the osteoporosis asso-
ciated with glucocorticoid use. Thirdly, the effect of 
using once-annually zoledronic acid on the osteoporo-
sis induced by the treatment for cancer is considered 
briefly. Finally, there is a commentary, which discusses 
the role and place of once-yearly zoledronic acid treat-
ment in primary and secondary osteoporosis.
primary Osteoporosis  
in Men and Women
Postmenopausal women  
with osteoporosis
Zoledronic acid has not been tested extensively in men 
with osteoporosis prior to fracture. Zoledronic acid was 
initially tested, in doses up to 4 mg annually, in post-
menopausal women with osteoporosis prior to fracture. 
Thus, in 351 postmenopausal women with low bone 
mineral density (a T score lower than -2), several reg-
imens of zoledronic acid infused over 5 minutes were 
shown to increase bone mineral density  similarly.6 
These regimens included 0.25 mg, 0.5 mg or 1 mg 
zoledronic acid at 3 monthly intervals, 2 mg at sixth 
monthly intervals, and an annual intravenous dose of 
4 mg.6 After one year, all regimens of zoledronic acid 
increased bone mineral density in the spine by 4%–5% 
and the femoral neck by 3%–4%, compared to the 
placebo group.6 No serious side effects were observed 
with zoledronic acid, but a few subjects experienced 
flu-like symptoms (e.g. myalgia, pyrexia), which were 
usually limited to the first administration of the zole-
dronic acid.6 Thus, myalgia was observed in 10% of 
the zoledronic acid 4 mg group, compared to 2% of 
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the placebo group, pyrexia in 15% versus 3%, and 
nausea in 13% versus 5%.6
Some of postmenopausal women (119) were 
continued on 4 mg zoledronic acid (Zometa®) 
yearly, and were followed for another 4 years.7 This 
extension showed continued benefit of zoledronic 
acid on bone turnover markers, with arthralgia as the 
most common adverse effect (18.2%), and no renal 
abnormalities.7 However, the subjects lost height, 
and six had fractures (one vertebral, and 5 non-
 vertebral; three in the foot, one in the ankle, and one 
in the radius.7 As, the initial part of this study had 
shown that maximal response to zoledronic acid was 
not obtained with 4 mg, this suggested, as had been 
shown with other bisphosphonates, that there was 
under dosing with zoledronic acid, and that better 
results (anti-fracture activity) may be obtained with a 
higher dose.7 A dose of 5 mg has been used in some of 
the further studies with zoledronic acid. Subsequent 
to the initial study, it was shown that the incidence of 
adverse effects with zoledronic acid could be reduced 
by increasing the infusion time from 5 to 15 minutes.
This bone mineral density study was not powered, 
or long enough, to determine whether this increase 
in bone mineral density translated into decreased 
clinical outcomes. Thus, it remained of interest to 
know whether this decrease in bone mineral density 
translated into reduced fractures, and this was tested 
in the Health Outcomes and Reduced Incidence 
with Zoledronic Acid Once Yearly Pivotal Fracture 
Trial (HORIZON-PFT), which was undertaken with 
postmenopausal women with osteoporosis, and used 
the higher 5 mg dose of zoledronic acid (Reclast®).8 
HORIZON-PFT enrolled postmenopausal women 
(65–89 years old) with a T score of -2.5 or less, with 
or without a vertebral fracture, or a T score of 1.5 or 
less with evidence of at least two mild or one moder-
ate vertebral fracture.8
The 7765 enrolled women were placed in two 
strata—the first stratum was women not taking any 
osteoporosis medication, and the second stratum was 
women taking an allowed osteoporosis medication 
at randomisation.8 Regardless of stratum, all women 
received oral daily calcium (1000–1500 mg) and 
vitamin D (400 to 1200 IU) and were randomised 
to placebo or a 15 minute intravenous injection of 
zoledronic acid 5 mg at baseline, 12, and 24 months.8 
The primary endpoints were new vertebral fractures 
in stratum 1 and hip fractures overall (strata 1 and 2). 
The incidence of new vertebral fractures in stratum 1 
women after 3 years was 10.9% in the placebo group 
and this was significantly reduced in the zoledronic 
acid group (3.3%).8 The incidence of hip fractures 
was 2.5% in the placebo group, and was reduced 
in the zoledronic acid group (1.4%).8 Women in the 
zoledronic acid group lost less height (-4.2 mm) than 
in the placebo group (-7.0 mm).8 The authors of this 
study suggest that the 70% reduction in vertebral-
fracture rate observed with zoledronic acid is greater 
than that previously reported for oral bisphosphonates 
(40–50%),8 and one factor that may contribute to this, 
is the poor adherence to oral bisphosphonates.
Around the infusion (#3 days after infusion), 
there was a higher incidence of pyrexia (16.1% vs. 
2.1%), myalgia (9.5% vs. 1.7%), influenza-like symp-
toms (7.8% vs. 1.6%), headache (7.1% vs. 2.3%) and 
arthralgia (6.3% vs. 2.0%) in the zoledronic acid than 
the placebo group.8 Fortunately, these adverse effects 
were mainly mild to moderate, and mostly short term.8
One unexpected finding in HORIZON-PFT 
was that the incidence of cardiac arrhythmias was 
significantly higher in the zoledronic-acid group (6.9%) 
than the placebo group (5.3%), and this included a 
higher incidence of serious atrial fibrillations with 
zoledronic acid (1.3% vs. 0.5%).8 For most of the 
subjects who developed atrial fibrillation, 47 of 50, 
the fibrillation occurred more than 30 days after the 
zoledronic acid infusion.8 The cardiac arrhythmias 
were not associated with either an increased incidence 
of stroke or cardiovascular death.8 The increased 
incidence of atrial fibrillation with zoledronic acid 
could not be explained, and the authors concluded 
that it “might be due to chance but should be further 
explored”.8 Further individual clinical trials have not 
found an increased incidence of atrial fibrillation with 
zoledronic acid (discussed below).
Subgroup analysis of HORIZON-PFT showed that 
the benefits of zoledronic acid on vertebral fractures were 
similar in most subgroups e.g. race, region, smoker 
vs. non-smoker, height, history of falls, walking 
distance, total hip bone mineral density.9 Zoledronic acid 
was more effective at preventing vertebral fractures 
vertebral fractures in those aged under 70 years, normal 
creatinine clearance, and bone mass index $25 mg/m2.9 
For non-vertebral and hip fractures, the benefits of 
zoledronic acid were similar in all subgroups.9
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The results from HORIZON-PFT were used to 
compare zoledronic acid with the other agents available 
for treatment of postmenopausal osteoporosis.10 This 
showed that zoledronic acid was more effective 
than the standard agents (risendronate, alendronate, 
ibandronate, strontium ranelate, raloxifene, or 
parathyroid hormone) at preventing vertebral, non-
vertebral, and hip fractures.10 Modelling showed 
that zoledronic acid also generates lesser total medi-
cal costs than the standard agents.10 The total costs 
included the cost of treatment strategies, which 
included prescription costs, and follow-up costs for 
3 years such as medical visits and laboratory tests, 
and the costs of managing vertebral, non-vertebral 
excluding hip, and hip fractures.10
A recent study shows that the benefits on zoledronic 
acid on bone mineral density in 581 postmenopausal 
women with low bone mass lasts up to two years.11 
After two years, the bone loss in the lumbar spine 
was 1.3% in the placebo group, compared to a gain 
of 5.5 and 4.3% with zoledronic acid administered 
once only or annually at the start of the two years, 
respectively.11 This suggests that it may be possible to 
extend the dosing of zoledronic acid beyond annually 
in postmenopausal women with osteoporosis.
After hip fracture in men and women
After hip fracture, people are at an increased risk 
of a further fracture. Thus, there are 10.4 further 
fractures/100 person-years, which is 2.52 times 
the rate observed in those people who have not 
had a hip fracture.12 Given this data, it would seem 
imperative that, after a hip fracture, subjects are 
treated with agents for osteoporosis, but this is not the 
case.13 Surprisingly, there had been no major studies of 
agents for osteoporosis after hip fracture until zole-
dronic acid was studied. The HORIZON Recurrent 
Fracture Trial (HORIZON-RFT), tested whether the 
ability of zoledronic acid to increase bone mineral 
density translated into beneficial outcomes in women 
and men with a recent hip fracture.14
HORIZON-RFT enrolled subjects who were 
50 years of age or older who had had a hip fracture 
that had undergone repair in the last 90 days.14 The 
hip fracture had to involve minimal trauma; defined 
as a fall from standing height or lower. Subjects were 
allowed to continue their use of nasal calcitonin, 
selective estrogen-receptor modulators, hormone 
replacement, tibolone, and of external hip protectors.14 
A total of 2127 subjects were randomized, and they 
were predominantly white (∼91%), female (∼77%), 
with a mean age of 75 years.14 At baseline, ∼42% had 
a T score at the femoral neck of -2.5 or less, indicating 
osteoporosis, and a further ∼34% had a T score .-2.5 
to -1.5 indicating osteopenia.14 All subjects received 
daily supplementation of oral calcium and vitamin D 
and received either zoledronic acid 5 mg or placebo 
by intravenous infusion within 90 days of surgical 
repair of the hip fracture and annually thereafter.14
The primary endpoint was a new clinical fracture, 
excluding facial and digital fractures, and fractures 
in abnormal bone (e.g. cancerous).14 It was planned 
to monitor the subjects for up to 5 years, but after a 
median follow-up of 1.9 years, the Independent Data 
and Safety Monitoring Board recommended the trial be 
stopped as it had surpassed the pre-specified efficacy 
boundaries.14 At that time, there were 139 fractures in 
the placebo group of 1062, and this was significant 
reduced to 92/1065 in the zoledronic acid group.14
Secondary endpoints included sites of fractures.14 
There were significantly less non-vertebral fractures in 
the zoledronic acid group (79) than in the placebo group 
(107), and less vertebral fractures in the zoledronic 
acid (21) than in the placebo group (39).14 There were 
also less hip fractures in the zoledronic acid group 
(23) than in the placebo group (33), but this did not 
reach significance.14 Secondary endpoints included 
death, and there were less deaths in the zoledronic 
acid group (101) than in the placebo group (141).14 
It is not known whether zoledronic acid has similar 
benefits in men and women, as no subgroup analysis 
of HORIZON-RFT has been published to date.
A similar number of adverse effects were reported 
in the zoledronic acid and placebo group. Myalgia 
occurred in significant more subjects in the zoledronic 
acid group (33, 3.1%) than the placebo group (9, 
0.9%), as did pyrexia after the first infusion (72, 
6.8% vs. 7, 0.9%).14 In this study, there was no excess 
of influenza-like symptoms, headache, or arthralgia 
with zoledronic acid over the placebo group.14 Also, 
there was no excess of cardiovascular events with 
zoledronic acid, including atrial fibrillation, which 
occurred in 29 subjects treated with zoledronic acid 
and 27 subjects treated with placebo.14 This contrasts 
with the HORIZON PFT where an increase in atrial 
fibrillation was observed with zoledronic acid.8
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elderly postmenopausal women
A posthoc analysis of HORIZON-PFT and 
HORIZON-RFT pooled the data for postmenopausal 
women (aged $75 years) with osteoporosis (T-score 
#-2.5 at femoral neck or $1 prevalent vertebral or 
hip fracture) or a recent hip fracture.15 In this group of 
3888, the risk of any clinical fracture was reduced with 
zoledronic acid 5 mg from 5.7 to 4.1% after 1 year, 
and from 16.6 to 10.8% after 3 years.15 The risk of 
clinical vertebral or non-vertebral fractures was also 
reduced by zoledronic acid after 3 years.15 The risk of 
a hip fracture was lower with zoledronic acid (2.8%) 
than with placebo (3.6%), but this did not reach statis-
tical significance in the aged $75 years, whereas the 
risk of hip fracture was significantly reduced in those 
less than 75 years.15
Major safety
The HORIZON Pivotal Fracture Trial in post-
menopausal osteoporosis demonstrated an excess 
in atrial fibrillation with zoledronic acid,8 whereas 
the HORIZON Recurrent Fracture Trial did not.14 
Both trials used 5 mg zoledronic acid intravenously 
annually, but the Pivotal Fracture Trial was evaluated 
after 3 years whereas the Recurrent Fracture Trial was 
followed-up after a 1.9 years. Thus, it is possible that 
atrial fibrillation is an effect of long term treatment 
with zoledronic acid, but there is no other evidence to 
support this to date.
Osteonecrosis of the jaw (necrotic bone in the 
oral cavity with local pain, soft-tissue swelling 
and/or loose teeth) is a rare complication with 
bisphosphonate treatment in osteoporosis. There was 
no evidence from HORIZON-PFT that zoledronic 
acid increased the incidence of osteonecrosis of the 
jaw in 3875 postmenopausal women with the once-
yearly zoledronic acid regimen after 3 years,8 and this 
was been confirmed by an independent, blinded adju-
dication committee.16
In subjects with cancer receiving bisphosphonates, 
the incidence of osteonecrosis of the jaw is dependent 
on the dose and duration of therapy, with an estimated 
incidence of 1%–12% after 36 months of exposure.5 
In osteoporosis, osteonecrosis of the jaw is rare 
with an estimated incidence of ,1 case per 100,000 
person-years of exposure, and it is not known whether 
this level is above that of the incidence in the general 
population.5
Glucocorticoid-induced  
secondary Osteoporosis
Glucocorticoids are commonly used in the treatment 
of inflammation and immunodulatory disorders, and 
are a major cause of secondary osteoporosis, and the 
recent HORIZON trial has shown that zoledronic acid 
increases bone mineral density under these conditions.17 
The HORIZON trial compared intravenous zoledronic 
acid 5 mg to oral risendronate 5 mg for the prevention 
and treatment of glucocorticoid-induced osteoporosis 
in 833 subjects taking glucocorticoids for conditions 
such as rheumatoid arthritis, polymyalgia rheumatica, 
systemic lupus erythematosus and asthma.17 The pre-
vention group had started glucocorticoids within the last 
3 months, the treatment group had been taking gluco-
corticoids for longer than 3 months.17 All groups were 
taking similar prednisolone-equivalent doses of gluco-
corticoids.17 After 12 months, the bone mineral density 
at the lumbar spine and femoral neck was increased 
more in the zoledronic acid group than the risendronate 
group in both the prevention and treatment subjects.17 
There were 5 new vertebral fractures in the zoledronic 
acid combined group of 416 subjects and 3 new frac-
tures in the risendronate group of 417 subjects.17 These 
low fracture rates in glucocorticoid treated subjects 
may be due to the effectiveness of both the zoledronic 
acid and risendronate.17 The authors considered that 
it was not ethical to undertake a placebo-controlled 
study of zoledronic acid in glucocorticoid-induced 
secondary osteoporosis,17 presumably because risen-
dronate had already been shown to reduce fractures in 
this secondary osteoporosis (reviewed in).18
Serious adverse effects were similar in both groups, 
but adverse effects were more common with zoledronic 
acid than risendronate.17 There were no cases of atrial 
fibrillation or osteonecrosis of the jaw attributed to 
zoledronic acid.17 Renal events occurred in 9 subjects 
with zoledronic acid and 6 subjects with risendronate, 
and all events were reversible.17 Six subjects in each 
group had ocular events and these were conjunctivitis 
(5) and blepharitis with zoledronic acid, and blurred 
vision (2), episcleritis, conjunctivitis, diplopia, and 
increase in lacrimation with risendronate.17 Pyrexia, 
myalgia and influenza-like illness were more common 
with zoledronic acid than with risendronate.17 There 
was no difference in health-related quality-of-life data 
between groups, but most subjects preferred intrave-
nous administration (∼80%) to oral administration.17
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During and after transplantation, immunosuppres-
sants including glucocorticoids are used, and contrib-
ute to the bone loss. Fractures occur in 20%–40% of 
subjects in recipients of liver, kidney, heart and lung 
transplants, and occur most frequently in the first year 
after transplantation.19 Zoledronic acid administered 
every 3 months (or more often) has been shown to be 
useful in preventing bone loss in liver and kidney trans-
plantation, and in allogeneic stem cell transplantation 
(reviewed in),20 and is not discussed further in this 
review, which is of zoledronic acid used once-yearly. 
It seems unlikely that zoledronic acid will be able to 
be used annually in liver transplantation, as the ability 
of zoledronic acid to prevent bone fractures after liver 
transplantation is lost within 12 months of treatment.21 
Thus, three ‘late’ asymptomatic fractures occurred in 
a group of 28 subjects who had had liver transplants, 
and been treated with zoledronic acid.21
Treatment for cancer Induced 
secondary Osteoporosis
The bone loss with anti-oestrogen treatment for 
hormone-sensitive breast cancer or androgen 
deprivation therapy for prostate cancer is major. 
Consequently, initially, zoledronic acid was given more 
often than once-yearly in cancer, as it is considered that 
zoledronic acid once-yearly would not be effective. 
The use of zoledronic acid more often than annually in 
the treatment of the osteoporosis associated with breast 
and prostate cancer has recently been reviewed.22 In 
addition to preventing osteoporosis, zoledronic acid 
may have anti-cancer properties in its own right.23 
Unfortunately, with increasing dose and increasing 
frequency of zoledronic acid use in cancer, there is an 
increased incidence of osteonecrosis of the jaw.5 Thus, 
recently, consideration has been given to improving 
the safety of zoledronic acid in the osteoporosis asso-
ciated with the treatment of cancer to improve by 
using it once-yearly.
Zoledronic acid once-yearly has been shown 
to reduce bone loss in androgen deprivation 
therapy-induced bone loss in men with hormone- naïve 
prostate carcinoma.24 In this study, 40 subjects with 
prostate cancer and bone metastases all received andro-
gen deprivation therapy (i.e. gonadotropin- releasing 
hormone agonists) and at the same time either receive 
zoledronic acid 4 mg or placebo.24 At baseline, there 
was no osteoporosis, but after 6 and 12 months, bone 
mineral density was decreasing in the placebo group.24 
In the zoledronic acid group, bone mineral density was 
increased at 6 months, and was at baseline levels after 
12 months. This indicates that zoledronic acid once-
yearly, administered at the same time as androgen 
deprivation therapy is started, may be suitable for pre-
venting bone loss in subjects being treated with andro-
gen deprivation therapy in prostate cancer.24 However, 
if the zoledronic acid is given to the subjects who 
have already become osteoporotic due to the androgen 
deprivation therapy, bone mineral density is reducing 
after one year.25 This shows that zoledronic acid once-
yearly is not suitable for use after the androgen depri-
vation therapy has induced osteoporosis.25
Other Indications for the use  
of Zoledronic Acid Once-yearly
Small pilot clinical trials have suggested that zole-
dronic acid may be useful in the treatment of the 
osteoporosis associated with β-thalassemia, stroke, 
spinal cord injury, HIV-infected men, monoclonal 
gammopathy of underdetermined significance and 
rheumatoid arthritis.20 Of these conditions, zoledronic 
acid annually has been assessed in stroke, spinal cord 
injury, and HIV-infected men, and shown to be suit-
able for use in stroke and HIV-infected men, but not 
in spinal cord injury. Thus, in a preliminary study, 
when 27 hemiplegic subjects were given calcium and 
 vitamin D and randomised to placebo or zoledronic 
acid 4 mg, the placebo group lost 5.5% of bone min-
eral density at the hemiplegic hip whereas the zole-
dronic acid group had no change after a year.26 On the 
unaffected hip, the placebo group lost bone mineral 
density (2.7%) whereas the zoledronic acid group had 
a small increase in bone mineral density (1%).26 There 
were no fractures during the study, and the number of 
falls (72%) was the same in both groups.26
In HIV-infected men, who were also receiving 
calcium and Vitamin D supplements, zoledronic acid 
4 mg annually over 2 years, the anti-resorptive effect 
of zoledronic acid was observed after 36 months.27 The 
authors suggest that it may possible to use zoledronic 
acid less frequently than annually in this group.27
In subjects loosing bone mineral density after 
spinal cord injury, a preliminary study has shown that 
a single injection of zoledronic acid 4 or 5 mg pre-
vented the bone loss at 6 months but not 12 months.28 
This suggests that zoledronic acid annually may be 
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useful in the treatment of the bone loss associated 
with stroke, but not spinal cord injury.
commentary
Dose of zoledronic acid
Although zoledronic acid at 4 mg/annually was 
used in the first major study with zoledronic 
acid in osteoporosis,6 subsequently studies have 
predominantly used 5 mg/annual. The reason for this 
change was that a maximal response to zoledronic 
acid on bone resorption markers was not obtained 
with 4 mg.7 However, to date, there are no studies that 
have determined whether the maximum response to 
zoledronic acid is produced by the 5 mg dose, and this 
should be tested. There are also no head-to-head stud-
ies comparing the two doses of zoledronic acid and, 
consequently, it is not possible to determine whether 
the 5 mg dose has added benefits over the 4 mg dose.
Zoledronic acid in men
Elderly men develop osteoporosis and have hip 
fractures. The National Osteoporosis Foundation 
estimated that 17 million men in the US will have 
osteoporosis or low bone mass in 2010.29 In men 
with osteoporosis, the oral bisphosphonates (alen-
dronate and risendronate) have been shown to reduce 
vertebral fracture, and to cause a small non-significant 
decrease in non-vertebral fractures.30 This suggests 
the more potent bisphosphonate zoledronic acid may 
be useful in treating men with osteoporosis. A trial 
has been undertaken to compare zoledronic acid with 
alendronate in men with osteoporosis,31 and when 
the findings are published, we will know whether 
zoledronic acid is more efficacious and/or safer in 
men with osteoporosis than alendronate.
In HORIZON-RFT, where zoledronic acid was 
shown to reduce the number of fractures in subjects 
after hip fracture, ∼23% of the subjects were male.14 
To date, no male subgroup analysis has been reported 
from this trial. Thus, this analysis should be reported, 
and/or a larger trial of zoledronic acid in men with 
osteoporosis after hip fracture should be undertaken.
Is zoledronic acid more beneficial  
than other agents in osteoporosis?
The HORIZON trials have clearly shown that 
zoledronic acid decreases fractures in postmeno-
pausal women, and in men and women after hip 
fracture, but is zoledronic acid more effective than 
other bisphosphonates or other agents for preventing 
fractures? There are no head to head trials of zoledronic 
acid with other bisphosphonates in primary osteopo-
rosis, and these are needed to give definite answers 
about effectiveness. However, as discussed by Black,8 
the 70% reduction in the vertebral fractures rate 
with zoledronic acid was greater than that observed 
previously for oral bisphosphonates (40%–50%) and 
for calcitonin or raloxifene. The recent HORIZON 
trial in glucocorticoid-induced osteoporosis showed 
that zoledronic acid had a greater effect on bone min-
eral density than risendronate,17 but this trial was not 
powered to determine whether there were any differ-
ences in fracture rates between the groups. Thus, trials 
are needed to determine whether the increased bone 
mineral density with zoledronic acid compared with 
risendronate in secondary osteoporosis translates into 
reduced vertebral and non-vertebral fractures.
Parathyroid hormone preparations (teriparatide32 
or human parathyroid hormone, 1–84)33 have a 
similar ability to zoledronic acid to decrease fractures. 
Both zoledronic acid and the parathyroid hormone 
compounds have reasonable good safety profiles 
in osteoporosis. Which is better? The results of the 
ongoing clinical trial in which zoledronic acid is being 
compared to teriparatide, and the combination of zole-
dronic acid and teriparatide, in women with osteopo-
rosis,34 may answer this question. It is also possible 
that, as zoledronic acid and teriparatide have different 
mechanisms of action, different subjects with osteo-
porosis may benefit from one or the other treatment.
Denosumab is a new treatment for bone loss. It is a 
human monoclonal antibody to the receptor activator 
of nuclear factor-κβ ligand (RANKL). RANKL is a 
cytokine that has an important role on the formation, 
function, and survival of osteoclasts. Denosumab 
prevents the interaction of RANKL with its receptor 
RANK on the osteoclasts, which leads the inhibition of 
osteoclasts-mediated bone resorption. In the Fracture 
Reduction Evaluation of Denosumab in Osteoporosis 
Every 6 months (FREEDOM) trial, after 36 months 
of treatment, denosumab was shown to reduce the 
incidence of vertebral and non-vertebral fractures in 
postmenopausal women with osteoporosis.35
Thus, zoledronic acid and denosumab seem to have 
a similar ability to reduce fractures in postmenopausal 
women with osteoporosis. Consequently, the choice 
Doggrell
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between zoledronic acid and denosumab in these 
women may be on the basis of safety.
Both zoledronic acid and denosumab have been 
shown to be well tolerated in the treatment of post-
menopausal osteoporosis. Zoledronic acid injection 
is associated with small excess of pyrexia, myalgia, 
influenza-like symptoms, headache, and arthralgia 
whereas denosumab caused a small excess in eczema, 
flatulence, and cellulitis.35
Only a direct comparator trial can provide a true 
comparison between zoledronic acid and denosumab 
in the treatment of postmenopausal osteoporosis. 
Such a trial should be undertaken. Also, as denosumab 
and zoledronic acid have different mechanisms, it is 
possible that they may have additive effects on bone 
mineral density and decreasing the incidence of frac-
tures. Thus, the comparator study should also include 
a group combining zoledronic acid and denosumab.
Adherence to zoledronic acid
It is assumed that adherence to annually administered 
zoledronic acid will be higher than to oral bisphospho-
nates or other agents administered daily or weekly in 
osteoporosis, but this has not been tested. For the first 
year of treatment, a subject with osteoporosis will be 
covered by a single injection of zoledronic acid, and 
is likely to be more adherent than a subject taking 
daily or weekly medication for osteoporosis. Subjects 
with osteoporosis are usually recalled for zoledronic 
acid treatment on an annual basis, and this should 
give good adherence, but this needs to be monitored.
Zoledronic acid and glucocorticoid-
induced secondary osteoporosis
The HORIZON study, of zoledronic acid once-yearly 
in subjects with glucocorticoid-induced osteoporosis, 
needs to be extended or repeated with larger numbers of 
subjects to determine whether zoledronic acid is equiv-
alent, superior, or inferior to risendronate at reducing 
fractures. It seems unlikely that zoledronic acid will be 
able to be used once-yearly in the bone loss associated 
with liver transplantation, as the ability of zoledronic 
acid to prevent bone fractures after liver transplantation 
is lost within 12 months of treatment.21
Zoledronic acid once-yearly and cancer
The increased dose and increasing frequency of 
zoledronic acid use in cancer, is associated with an 
increased incidence of osteonecrosis of the jaw.5 
To avoid this, consideration is being given to using 
zoledronic acid once-yearly for the osteoporosis 
associated with the treatment of cancer. Zoledronic 
acid once-yearly has been shown to reduce bone loss 
in androgen deprivation therapy-induced bone loss in 
men with hormone-naïve prostate carcinoma provided 
it is given at the same time as the androgen deprivation 
therapy,24 and not when osteoporosis has developed.25 
Further studies need to be undertaken to determine 
whether zoledronic acid once-yearly can be effica-
cious at preventing bone loss and safe in other bone 
loss associated with cancer treatment e.g. in breast 
cancer.
Conclusion: what role does zoledronic 
acid once-yearly have in the prevention 
of non-vertebral osteoporotic fractures?
In many clinical trials with zoledronic acid in 
osteoporosis, the primary outcome is change in bone 
mineral density. It is assumed that an increase in bone 
mineral density (surrogate endpoint) will lead to a 
decrease in fractures (clinical endpoint) and this has 
been confirmed for zoledronic acid once-yearly in post-
menopausal women with osteoporosis, and men and 
women with osteoporosis after a hip fracture. Thus, 
zoledronic acid is an important medicine for the pre-
vention of fractures in these cohorts. However, in glu-
cocorticoid-induced secondary osteoporosis, the major 
trial with zoledronic acid once-yearly was too small or 
too short to detect any changes in clinical outcomes, 
and consequently we cannot be absolutely certain that 
the change in bone mineral density will be sufficient 
to improve clinical outcomes. Also, the role, if any, of 
zoledronic acid once-yearly in subjects with bone loss 
due to cancer treatment, needs to be determined.
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